124 related articles for article (PubMed ID: 23752435)
1. Cancer metabolism in breadth and depth.
Chun MG; Shaw RJ
Nat Biotechnol; 2013 Jun; 31(6):505-7. PubMed ID: 23752435
[No Abstract] [Full Text] [Related]
2. Cancer. Silencing a metabolic oncogene.
Kim J; DeBerardinis RJ
Science; 2013 May; 340(6132):558-9. PubMed ID: 23641103
[TBL] [Abstract][Full Text] [Related]
3. Therapeutics: targeting an oncometabolite.
McCarthy N
Nat Rev Cancer; 2013 Jun; 13(6):383. PubMed ID: 23640211
[No Abstract] [Full Text] [Related]
4. Releasing the block: setting differentiation free with mutant IDH inhibitors.
Pirozzi CJ; Reitman ZJ; Yan H
Cancer Cell; 2013 May; 23(5):570-2. PubMed ID: 23680144
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
6. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
Son J; Lyssiotis CA; Ying H; Wang X; Hua S; Ligorio M; Perera RM; Ferrone CR; Mullarky E; Shyh-Chang N; Kang Y; Fleming JB; Bardeesy N; Asara JM; Haigis MC; DePinho RA; Cantley LC; Kimmelman AC
Nature; 2013 Apr; 496(7443):101-5. PubMed ID: 23535601
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.
Park SW; Davison JM; Rhee J; Hruban RH; Maitra A; Leach SD
Gastroenterology; 2008 Jun; 134(7):2080-90. PubMed ID: 18549880
[TBL] [Abstract][Full Text] [Related]
10. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
[TBL] [Abstract][Full Text] [Related]
11. Metabolism: Taking it all in.
Seton-Rogers S
Nat Rev Cancer; 2013 Jul; 13(7):438. PubMed ID: 23739049
[No Abstract] [Full Text] [Related]
12. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish.
Shi X; He BL; Ma AC; Guo Y; Chi Y; Man CH; Zhang W; Zhang Y; Wen Z; Cheng T; Leung AY
Blood; 2015 May; 125(19):2974-84. PubMed ID: 25778530
[TBL] [Abstract][Full Text] [Related]
13. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.
Commisso C; Davidson SM; Soydaner-Azeloglu RG; Parker SJ; Kamphorst JJ; Hackett S; Grabocka E; Nofal M; Drebin JA; Thompson CB; Rabinowitz JD; Metallo CM; Vander Heiden MG; Bar-Sagi D
Nature; 2013 May; 497(7451):633-7. PubMed ID: 23665962
[TBL] [Abstract][Full Text] [Related]
14. IDH1 inhibitor shows promising early results.
Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779
[TBL] [Abstract][Full Text] [Related]
15. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
16. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR
Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652
[TBL] [Abstract][Full Text] [Related]
18. Roles for KRAS in pancreatic tumor development and progression.
di Magliano MP; Logsdon CD
Gastroenterology; 2013 Jun; 144(6):1220-9. PubMed ID: 23622131
[TBL] [Abstract][Full Text] [Related]
19. Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway.
Sakata K; Kato S; Fox JC; Shigemori M; Morimatsu M
J Neuropathol Exp Neurol; 2002 Nov; 61(11):975-83. PubMed ID: 12430714
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mutant IDH1 in acute myeloid leukaemia.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
[No Abstract] [Full Text] [Related]
[Next] [New Search]